Author:
Rugo Hope S,Bardia Aditya,Marmé Frederik,Cortés Javier,Schmid Peter,Loirat Delphine,Trédan Olivier,Ciruelos Eva,Dalenc Florence,Gómez Pardo Patricia,Jhaveri Komal L,Delaney Rosemary,Valdez Theresa,Wang Hao,Motwani Monica,Yoon Oh Kyu,Verret Wendy,Tolaney Sara M
Reference28 articles.
1. Annual report to the nation on the status of cancer, 1975-2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state;Kohler;J Natl Cancer Inst,2015
2. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status;Howlader;J Natl Cancer Inst,2014
3. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer;Gennari;Ann Oncol,2021
4. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study;Cortes;Lancet,2011
5. Subgroup analyses from a phase 3, open-label, randomized study of eribulin mesylate versus capecitabine in pretreated patients with advanced or metastatic breast cancer;Twelves;Breast Cancer,2016
Cited by
99 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献